Aayush Sisodia, MSHI, BDS

Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.

Health plans can use routine pharmacy claims to identify members at high risk for early discontinuation of glucagon-like peptide-1 receptor agonists and deliver targeted, equity-conscious adherence support.

A reproducible Prior Authorization Friction Index enables payers to identify glucagon-like peptide-1 delays and rework, reduce avoidable barriers, and monitor utilization, budgets, and equity in real-world practice.